Repligen Reports Fourth Quarter 2017 Financial Results, Provides Guidance for 2018

Biotech Investing

Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter and year ended December 31, 2017. Provided in this press release are financial highlights for these periods, our financial guidance for the year 2018 and access information for today’s webcast and conference call. As quoted …

As quoted in the press release:

Total revenue increased by 63% year-over-year, to $41.6 million
Spectrum product sales contributed $11.8 million, a pro forma increase of 19% year-over-year
GAAP gross margin was 54% and adjusted gross margin expanded by 380 bps to 57.1%
GAAP fully-diluted EPS increased 88% to $0.27, including the positive $0.22 impact of tax reform, versus $0.15 for the fourth quarter of 2016
Adjusted (non-GAAP) EPS increased 116% to $0.20 versus $0.09 for the fourth quarter of 2016

Click here to read the full press release.

conference call eps financial highlights financial results guidance life sciences webcast Biotech Investing